TY - JOUR T1 - Accelerated RNA detection using tandem CRISPR nucleases JF - medRxiv DO - 10.1101/2021.03.19.21253328 SP - 2021.03.19.21253328 AU - Tina Y. Liu AU - Gavin J. Knott AU - Dylan C. J. Smock AU - John J. Desmarais AU - Sungmin Son AU - Abdul Bhuiya AU - Shrutee Jakhanwal AU - Noam Prywes AU - Shreeya Agrawal AU - María Díaz de León Derby AU - Neil A. Switz AU - Maxim Armstrong AU - Andrew R. Harris AU - Emeric J. Charles AU - Brittney W. Thornton AU - Parinaz Fozouni AU - Jeffrey Shu AU - Stephanie I. Stephens AU - G. Renuka Kumar AU - Chunyu Zhao AU - Amanda Mok AU - Anthony T. Iavarone AU - Arturo M. Escajeda AU - Roger McIntosh AU - Shin E. Kim AU - Eli J. Dugan AU - IGI Testing Consortium AU - Katherine S. Pollard AU - Ming X. Tan AU - Melanie Ott AU - Daniel A. Fletcher AU - Liana F. Lareau AU - Patrick D. Hsu AU - David F. Savage AU - Jennifer A. Doudna Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/24/2021.03.19.21253328.abstract N2 - Direct, amplification-free detection of RNA has the potential to transform molecular diagnostics by enabling simple on-site analysis of human or environmental samples. CRISPR-Cas nucleases offer programmable RNA-guided recognition of RNA that triggers cleavage and release of a fluorescent reporter molecule1,2, but long reaction times hamper sensitivity and speed when applied to point-of-care testing. Here we show that unrelated CRISPR nucleases can be deployed in tandem to provide both direct RNA sensing and rapid signal generation, thus enabling robust detection of ∼30 RNA copies/microliter in 20 minutes. Combining RNA-guided Cas13 and Csm6 with a chemically stabilized activator creates a one-step assay that detected SARS-CoV-2 RNA from nasopharyngeal samples with PCR-derived Ct values up to 29 in microfluidic chips, using a compact imaging system. This Fast Integrated Nuclease Detection In Tandem (FIND-IT) approach enables direct RNA detection in a format amenable to point-of-care infection diagnosis, as well as to a wide range of other diagnostic or research applications.Competing Interest StatementD.F.S. is a co-founder of Scribe Therapeutics and a scientific advisory board member of Scribe Therapeutics and Mammoth Biosciences. P.D.H. is a cofounder of Spotlight Therapeutics and serves on the board of directors and scientific advisory board, and is a scientific advisory board member to Vial Health and Serotiny. The Regents of the University of California have patents issued and/or pending for CRISPR technologies on which J.A.D., T.Y.L., P.D.H., N.P., D.F.S., D.C.J.S., S.E.K., B.W.T., E.J.C., and G.J.K. are inventors. M.O., P.F., G.R.K., D.F., S.S., and N.A.S. have also filed patent applications related to this work. J.A.D. is a cofounder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, Intellia Therapeutics and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Synthego, Algen Biotechnologies, Felix Biosciences and Inari. J.A.D. is a Director at Johnson & Johnson and has research projects sponsored by Biogen, Pfizer, AppleTree Partners and Roche.Funding StatementThis work was supported by DARPA under award N66001-20-2-4033. The views, opinions and/or findings expressed are those of the authors and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government. The work was also supported by the Howard Hughes Medical Institute, and the National Institutes of Health (NIH) (R01GM131073 and DP5OD021369 to P.D.H., R01GM127463 to D.F.S., and grant 5R61AI140465-03 to J.A.D., D.A.F., and M.O). A mass spectrometer was also purchased with NIH support (grant 1S10OD020062-01). This work was made possible by a generous gift from an anonymous private donor in support of the ANCeR diagnostics consortium. We also thank the David & Lucile Packard Foundation and the Shurl and Kay Curci Foundation for their generous support of this project. We thank Integrated DNA Technologies and Synthego Corporation for support with oligonucleotide modifications and synthesis, and Shanghai ChemPartner for expression and purification of the EiCsm6 protein. We thank QB3 MacroLabs for subcloning TtCsm6, A. J. Aditham for assistance purifying TtCsm6, and D. Colognori for helpful discussions. J.A.D. is an HHMI investigator. G.J.K. acknowledges support from the NHMRC (Investigator Grant, EL1, 1175568). B.W.T. is supported by a National Science Foundation (NSF) Graduate Fellowship. P.F. was supported by the NIH/NIAID (F30AI143401). M.D.d.L.D. was supported by the UC MEXUS-CONACYT Doctoral Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Dr. Rebecca Armstrong in the Office for Protection of Human Subjects at UC Berkeley determined that this study did not meet the threshold definition of "human subjects research" set forth in Federal Regulations at 45 CFR 46 or at 21 CFR 50. This determination is based on the understanding that study procedures were limited to secondary data analysis of non-identifiable biospecimens, for which there was no link to identifiable subject information. In addition, the research data in this study will not be held for inspection by nor submitted to the FDA. Accordingly, this project did not fall within the scope of the Committee's responsibilities, and no further approval from the Office is needed at this time.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData that support the findings of this study are available from the corresponding author upon request. Plasmids used in this study will be made available through Addgene. All custom code used for analysis will be made publicly accessible on Github or upon request. Sequences of oligonucleotides used in this study are available in Extended Data Table 3. ER -